FDA Import Policy Discourages Promotion, Not Reimbursement – McClellan
Executive Summary
FDA's letter to health insurers about drug importation is meant to ensure they do not encourage policy holders to purchase drugs from outside the U.S., not to prohibit them from covering individuals who purchase Canadian drugs for personal use, FDA Commissioner McClellan told a Senate Appropriations/Agriculture Subcommittee hearing May 22
You may also be interested in...
Medicare Rx Must Address “Anger” Over Drug Prices, AARP’s Rother Says
AARP remains convinced that Congress needs to address the high price of prescription drugs
Medicare Rx Must Address “Anger” Over Drug Prices, AARP’s Rother Says
AARP remains convinced that Congress needs to address the high price of prescription drugs
Public Sector Reimportation Programs Violate FD&C Act, FDA Tells Calif.
California cannot encourage Rx importation from Canada directly or indirectly without exposing itself to liability under the FD&C Act, FDA told the state Attorney General